2024
Aldehydes alter TGF-β signaling and induce obesity and cancer
Yang X, Bhowmick K, Rao S, Xiang X, Ohshiro K, Amdur R, Hassan M, Mohammad T, Crandall K, Cifani P, Shetty K, Lyons S, Merrill J, Vegesna A, John S, Latham P, Crawford J, Mishra B, Dasarathy S, Wang X, Yu H, Wang Z, Huang H, Krainer A, Mishra L. Aldehydes alter TGF-β signaling and induce obesity and cancer. Cell Reports 2024, 43: 114676. PMID: 39217614, PMCID: PMC11560041, DOI: 10.1016/j.celrep.2024.114676.Peer-Reviewed Original ResearchAldehyde dehydrogenase 2Small interfering RNADisease progression to cancerPro-oncogenic phenotypeTGF-bProgression to cancerGrowth factor BTGF-b signalingHuman metabolic syndromeSteatotic liver diseasePotential therapeutic targetMetabolic syndromePro-fibroticInduce obesityTherapeutic inhibitionLiver diseaseCurrent treatmentSmad3 signalingGlucose handlingTherapeutic targetFunctional phenotypeDehydrogenase 2Improve glucose handlingSPTBN1ObesityHypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)
Habeshian T, Peeri N, De Vivo I, Schouten L, Shu X, Cote M, Bertrand K, Chen Y, Clarke M, Clendenen T, Cook L, Costas L, Dal Maso L, Freudenheim J, Friedenreich C, Gallagher G, Gierach G, Goodman M, Jordan S, La Vecchia C, Lacey J, Levi F, Liao L, Lipworth L, Lu L, Matias-Guiu X, Moysich K, Mutter G, Na R, Naduparambil J, Negri E, O'Connell K, O'Mara T, Hernández I, Palmer J, Parazzini F, Patel A, Penney K, Prizment A, Ricceri F, Risch H, Sacerdote C, Sandin S, Stolzenberg-Solomon R, van den Brandt P, Webb P, Wentzensen N, Wijayabahu A, Wilkens L, Xu W, Yu H, Zeleniuch-Jacquotte A, Zheng W, Du M, Setiawan V. Hypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Epidemiology Biomarkers & Prevention 2024, 33: 788-795. PMID: 38530242, PMCID: PMC11145161, DOI: 10.1158/1055-9965.epi-23-1444.Peer-Reviewed Original ResearchConceptsEpidemiology of Endometrial Cancer ConsortiumRisk of endometrial cancerComponents of metabolic syndromeCancer ConsortiumRisk factorsAssociated with endometrial cancer riskIncidence rates of endometrial cancerMultivariable unconditional logistic regression modelStronger magnitude of associationEtiology of endometrial cancerStudy designUnconditional logistic regression modelsIncreased risk of endometrial cancerEndometrial cancer riskRates of endometrial cancerUsers of postmenopausal hormone therapyConfidence intervalsRising prevalence of obesityPrevalence of obesityEndometrial cancerMagnitude of associationEndometrial cancer casesMetabolic syndromeBody mass indexLogistic regression models
2008
Non-High-Density Lipoprotein Cholesterol in Patients With Metabolic Syndrome
Huang J, Parish R, Mansi I, Yu H, Kennen E, Davis T, Carden D. Non-High-Density Lipoprotein Cholesterol in Patients With Metabolic Syndrome. Journal Of Investigative Medicine 2008, 56: 931. DOI: 10.231/jim.0b013e318182080a.Peer-Reviewed Original ResearchNon-HDL cholesterolCoronary artery diseaseMetabolic syndromeLipoprotein cholesterolArtery diseaseMS patientsTherapeutic targetCross-sectional chart reviewLow-density lipoprotein cholesterolNon-HDL levelsCardiovascular risk factorsDensity lipoprotein cholesterolPublic hospital patientsAlternative therapeutic targetsCritical therapeutic targetExcessive hypertriglyceridemiaChart reviewLow HDLTotal cholesterolLDL cholesterolTriglyceride levelsRisk factorsHospital patientsHigh prevalencePatientsNon-High-Density Lipoprotein Cholesterol in Patients with Metabolic Syndrome
Huang J, Parish R, Mansi I, Yu H, Kennen E, Davis T, Carden D. Non-High-Density Lipoprotein Cholesterol in Patients with Metabolic Syndrome. Journal Of Investigative Medicine 2008, 56: 931-936. PMID: 18753978, DOI: 10.2310/jim.0b013e318182080a.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolCoronary artery diseaseMetabolic syndromeLipoprotein cholesterolArtery diseaseMS patientsTherapeutic targetCross-sectional chart reviewLow-density lipoprotein cholesterolNon-HDL levelsCardiovascular risk factorsDensity lipoprotein cholesterolPublic hospital patientsAlternative therapeutic targetsCritical therapeutic targetExcessive hypertriglyceridemiaChart reviewLow HDLTotal cholesterolLDL cholesterolTriglyceride levelsRisk factorsHospital patientsHigh prevalencePatients
2006
266 NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN THE METABOLIC SYNDROME.
Huang J, Parish R, Yu H, Bass P, Mansi I, Kennen E, Davis T, Carden D. 266 NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN THE METABOLIC SYNDROME. Journal Of Investigative Medicine 2006, 54: s303. DOI: 10.2310/6650.2005.x0008.265.Peer-Reviewed Original ResearchLow-density lipoprotein cholesterolHigh-density lipoprotein cholesterolLow high-density lipoprotein cholesterolMetabolic syndromeLipoprotein cholesterolCoronary artery disease preventionPrevalence of MSDiagnosis of MSPercent of patientsPrevalence of dyslipidemiaNon-HDL cholesterolDensity lipoprotein cholesterolHigher atherogenic potentialCardiovascular morbidityCentral obesityLipid managementElevated BPElevated triglyceridesHigh triglyceridesMS patientsAggressive loweringNCEP criteriaInsulin resistanceLipid therapyPatient population
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply